cbdMD’s Post

A recent study highlighted by HIGH TIMES has shown promising weight loss effects from the cannabinoids, THCV and CBD. Titled “Weight Loss and Therapeutic Metabolic Effects of Tetrahydrocannabivarin (THCV)-Infused Mucoadhesive Strips,” the study examined the impact of these cannabinoids on metabolic syndrome. Metabolic syndrome can lead to serious conditions like diabetes and increased stroke or heart attack risk. The study involved 44 participants, averaging 51.75 years old, who received either a low dose (8 mg THCV/10 mg CBD), a high dose (16 mg THCV/20 mg CBD), or a placebo via oral strips daily for 90 days. The findings were significant: participants using the THCV/CBD strips experienced notable weight loss, reduced abdominal girth, and improvements in systolic blood pressure and cholesterol levels. The higher dose group showed the most pronounced improvements, highlighting the superior effectiveness of the 16 mg THCV/20 mg CBD dosage. We continue to explore the therapeutic benefits of cannabinoids, striving to enhance health and wellness through innovative products. Learn more: https://lnkd.in/dF4jehAQ

Amgen's obesity drug, MariTide, has shown promising early results in stimulating weight loss without major side effects in both animals and humans, potentially requiring only once-a-month dosing. Early clinical trials indicate significant and durable weight loss, with participants maintaining reduced body weight for up to five months post-treatment. These findings, alongside the drug's unique mechanism of action that differs from competitors like Eli Lilly’s Zepbound by modulating appetite and insulin secretion through targeting GLP-1 and GIP receptors in specific ways, suggest MariTide could offer a new, effective treatment option for obesity management. #Amgen #ObesityTreatment #MariTide #ClinicalTrials #WeightLoss #GLP1GIPReceptors

#peptides research 🧬 Tirzepatide is a peptide that acts as an agonist on two target sites Glucagon-like peptide-1 (GLP-1) and Glucose-dependent insulinotropic polypeptide (GIP). A phase 3 trial lasting 72 weeks was done on obese subjects comparing once weekly tirzepatide injections (at 3 dosage ranges 5 mg, 10 mg, or 15 mg) vs placebo. At 72 weeks -the mean change in weight for the 5 mg group was 16% (a weight reduction of 35.5 lbs) -the mean change in weight for the 10 mg group was 21.4% (a weight reduction of 48.9 lbs) -the mean change in weight for the 15 mg group was 22.5% (a weight reduction of 52 lbs) -the mean change for the placebo group was 2.4% (a weight reduction of 5.3 lbs). #obesity #wealthmanagement #glucagon #research

🚨 Retatrutide: A new medication from Eli Lilly with TRIPLE mechanism could change the future of diabetes and obesity managemant !!! A phase 2 trial recently published in NEJM and presented at American Diabetes Association's annual meeting 2023 for Retatrutide which is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors ( GIP /GLP-1 /GCG) for the treatment of obesity. Retatrutide has the potential to provide greater weight loss benefits than any drug currently on the market reach to 24% loss of body weight for 48 weeks as in the study. A phase 3 trial expected to run with larger populations to assess it’s efficacy and safety for obesity. Tirzepatide (also Eli Lilly drug) recently approved from FDA for Type 2 diabetes with advantage of body loss is working with double mechanism (GIP/GLP-1 receptor agonists). The new medication works with one more added mechanism ( mimic glucagon hormone) which may reduce appetite and help metabolism run more efficiently. The future of Type 2 diabetes and obesity management is very promising 👍🏻 SM https://lnkd.in/d6Bi9a-2 #obesity #diabetes #Retatrutide #weight_loss #ADA23 #Eli_lilly

🌟 𝐃𝐲𝐧𝐚𝐦𝐢𝐜 𝐆𝐫𝐨𝐰𝐭𝐡 𝐢𝐧 𝐭𝐡𝐞 𝐒𝐭𝐚𝐭𝐢𝐧 𝐌𝐚𝐫𝐤𝐞𝐭! 🌟 𝐂𝐥𝐢𝐜𝐤 𝐇𝐞𝐫𝐞, 𝐓𝐨 𝐆𝐞𝐭 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 https://lnkd.in/gdpyddzM The statin market is witnessing significant growth driven by the rising prevalence of cardiovascular diseases (CVDs) and increasing awareness about cholesterol management. Statins, a class of lipid-lowering medications, play a crucial role in reducing cardiovascular risk by lowering blood cholesterol levels, making them one of the most widely prescribed drugs globally. 🔍 Key Market Drivers: Increasing Prevalence of Cardiovascular Diseases: The growing incidence of heart disease and stroke, often linked to lifestyle factors such as poor diet and lack of exercise, is fueling the demand for statins. Aging Population: An aging global population, particularly in developed countries, is driving higher statin prescriptions as older adults are more susceptible to high cholesterol and cardiovascular conditions. Preventive Healthcare Awareness: Rising awareness about preventive healthcare and the importance of maintaining healthy cholesterol levels is encouraging more people to seek statin therapy. 📊 Market Trends: Development of Combination Therapies: The trend towards combination therapies that include statins along with other cardiovascular drugs is gaining momentum, offering enhanced efficacy and convenience. Generic Statins: The expiration of patents for several blockbuster statins has led to an influx of generic versions, making these medications more affordable and accessible. Personalized Medicine: Advances in genetic testing and personalized medicine are enabling tailored statin therapies, optimizing treatment effectiveness based on individual patient profiles. #Company AstraZeneca Merck Pfizer Amgen AUROBINDO PHARMA LTD #Type Astrovastatin Fluvastatin Lovastatin Pravastatin Simvastatin Others #Application Cardiovascular Disorders Obesity Inflammatory Disorders Others #Statins #CardiovascularHealth #CholesterolManagement #PreventiveHealthcare #Pharmaceuticals #HealthcareInnovation #GenericDrugs #CombinationTherapies #PersonalizedMedicine #MedicalResearch #MarketTrends #HeartHealth #PatientCare #DrugDevelopment #PharmaCollaborations

#D-Allulose    Rare sugar D-allulose: Potential role and therapeutic monitoring in maintain#Obesity and type 2 #diabetes mellitus DOI: https://doi: 10.1016/j.pharmthera.2015.08.004 To appear in: Pharmacology and Therapeutics Role and therapeutic monitoring in maintaining obesity and type 2 diabetes mellitus, https://lnkd.in/gxKa38yk

Promising results for Eli Lilly's obesity drug, known as tirzepatide or #Mounjaro, in two late-stage studies. The drug is a once-weekly injectable medication that belongs to a class of drugs called glucagon-like peptide-1 receptor agonists (GLP-1 RAs). GLP-1 RAs work by mimicking the effects of a hormone called glucagon-like peptide-1, which stimulates insulin secretion, reduces appetite, and promotes weight loss. Patients lost an average of 26.6% of their weight after intensive lifestyle changes or continued treatment, compared to a placebo. The drug is expected to become a blockbuster treatment if approved for obesity, and is a key growth driver for Lilly. #EliLilly #obesitytreatment

Why to Consider Using Milk Thistle? Liver Protection Milk thistle extracts, with their antioxidant, anti-inflammatory, and immunomodulatory properties, offer significant liver protection from toxins. Silymarin, a key component, prevents fat oxidation and boosts detoxification pathways, maintaining glutathione levels, a crucial antioxidant. It also modulates inflammation by inhibiting inflammatory cytokines like tumor necrosis factor-alpha (TNF-α). As a result, silymarin shields the liver from damage caused by toxins, alcohol, and drugs. Additionally, silymarin supports liver cell regeneration by enhancing protein synthesis. Support for Liver Diseases Extensive research highlights the therapeutic potential of milk thistle for liver conditions like fatty liver disease (NAFLD), cirrhosis, and hepatitis. Silymarin has shown promise in improving liver function, reducing liver enzymes (ALT and AST) and bilirubin levels. By modulating enzymes that cause cellular damage, silymarin helps reduce fibrogenesis, thus mitigating fibrosis and the progression to cirrhosis. While not a standalone treatment for hepatitis, silymarin is beneficial as a complementary therapy, reducing viral load and overall mortality in hepatitis-related cirrhosis when used with conventional medications. #LiverHealth #MilkThistle #Silymarin #Detox #NaturalRemedies #HerbalMedicine #LiverSupport #Health #Wellness #Antioxidants #Inflammation #LiverDisease

https://lnkd.in/eKbkMhbn I have been incredibly vigilant about genetic differences & specifically focused on fat & starch metabolism. Science still lacks the complete biochemical & pathophysiology of fiber digestion. Our intestines take fiber & make short chain fatty acids which go back to the liver to be re-packaged as important blood lipids. Despite claims elsewhere, the human body takes all food & makes important constituents to provide energy & cell renewal. That is part of how fiber "prevents" heart disease. The other portion of fiber's role in health is via stimulation of incretins, specifically GLP-2. GLP-2 is a big harder for pharmaceutical companies to work with & was assigned to treatment of people with short bowel disease. However the best research I found on GLP-2 was two-fold: it prevents bone loss & possibly osteoporosis, plus it seems to heal the actual cells of our intestine. Additionally, GLP-2 may prevent some of the kidney damage prevalent with all type of diabetes. This paper looks at high fat diets. As I eluded in another post today, I am actually part Native American. In my family of origin, the next statement would be, "which part" to which my mother would respond, "looks like you belong to the Blackfoot tribe, go wash your feet & wear shoes when you are outside". I certainly do NOT quality for special benefits because of my blood quantum nor would I seek any such special treatment. That said, many of the folks in my neighborhood, including my next door neighbor, developed gallbladder disease & had to get their gallbladder taken out. My own brother, the one nicknamed, "Little Beaver" because he was a late bloomer & had a darker complexion than his siblings, finally agreed to have his gallbladder removed. The prevalence of gallbladder disease during my years of employment as a Registered Nurse was quite high in the Southwest.